UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company ...

Financing led by Velan Capital with participation from new and existing healthcare-focused institutional investors and insidersCapital raise to ...

Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday March 12, 2025 COPENHAGEN, Denmark; February 13, 2025 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on ...

Vaccinations alone may not be enough to protect people with compromised immune systems from infection, even if the vaccine has generated the production of antibodies, new research from the University ...

DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, ...

Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report for the financial year 2024 on Form 20-F with the U.S. Securities and Exchange Commission (SEC), incorporating by ...

Company Announcement COPENHAGEN, Denmark; February 12, 2025 - Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024 ...

Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at the Peter Doherty Institute of Infection and Immunity (Doherty Institute), in ...